Who Owns Cytek Company?

Who Owns Cytek Biosciences?

Understanding Cytek Biosciences' ownership is key for investors and partners in the life sciences. The company went public in July 2021, changing its ownership landscape.

Cytek Biosciences, a leader in cell analysis, has a history rooted in innovation. Its journey from a private entity to a publicly traded company significantly altered its stakeholder base.

As of August 2025, Cytek Biosciences is a publicly traded company on NASDAQ under the ticker CTKB. Its market capitalization stands at approximately $509 million, with 127 million shares outstanding. This public status means ownership is distributed among various shareholders, including institutional investors and individual stockholders. The company's innovative Full Spectrum Profiling (FSP) technology is central to its market position, driving its valuation and investor interest. For a deeper look into its market environment, consider a Cytek PESTEL Analysis.

Cytek Biosciences was established in 1992 by Dr. Wenbin Jiang and Dr. Ming Yan. These co-founders have played pivotal roles in the company's trajectory, with Dr. Jiang serving as CEO and Chairman since 2014, and Dr. Yan as CTO and a board member since 2015. Their continued leadership suggests significant early ownership, though precise initial equity details are not publicly disclosed.

Founding Visionaries

Dr. Wenbin Jiang and Dr. Ming Yan founded Cytek Biosciences in 1992. Their combined expertise in scientific innovation and research leadership laid the groundwork for the company's future growth.

Early Leadership Roles

Dr. Jiang has been CEO and Chairman since December 2014, while Dr. Yan has served as CTO and a board member since 2015. These sustained leadership positions highlight their ongoing influence.

Intellectual Property

Dr. Wenbin Jiang's significant contribution is evidenced by his portfolio of over 95 U.S. patents, reflecting a strong foundation in technological innovation.

Research and Development Focus

Dr. Ming Yan brings over two decades of research and development experience to the company. This deep expertise is crucial for the company's technological advancements.

Early Stage Funding

In its private phase, the company secured funding, including a Series B round in 2016 that raised $11.5 million. This capital supported development and commercialization efforts.

Undisclosed Early Stakeholders

While specific details of early investors or friends and family stakes are not public, the founders' continued leadership suggests substantial initial ownership and commitment.

During its early, private stages, Cytek Biosciences actively sought funding to advance its technological development and market penetration. A notable instance of this was the Series B funding round in 2016, which successfully garnered $11.5 million. This capital infusion, along with subsequent funding rounds, was instrumental in supporting the company's growth. Public records do not offer extensive details regarding angel investors or other early stakeholders who may have acquired equity during this formative period. It is common for private companies not to disclose specific agreements like vesting schedules or buy-sell clauses from these early phases until after a public listing. The enduring leadership and active involvement of the co-founders, Drs. Jiang and Yan, strongly indicate their foundational vision and sustained influence on the company's strategic direction from its inception. Understanding the company's market positioning is key to understanding its ownership structure, as detailed in this article on the Target Market of Cytek.

Founders' Enduring Influence

The continued leadership roles of Dr. Wenbin Jiang and Dr. Ming Yan as CEO, Chairman, CTO, and board members underscore their foundational vision and sustained impact on Cytek Biosciences.

• Dr. Wenbin Jiang: Co-founder, CEO, Chairman, holder of over 95 U.S. patents.
• Dr. Ming Yan: Co-founder, CTO, Board Member, with over two decades of R&D experience.
• Early funding rounds, such as the 2016 Series B ($11.5 million), supported company development.
• Precise initial equity splits and early investor details are not publicly disclosed, which is typical for private companies.

Cytek Biosciences' ownership structure saw a significant shift with its Initial Public Offering (IPO) on July 23, 2021, when it began trading on The Nasdaq Global Select Market under the symbol 'CTKB'. This event marked its transition from private to public ownership, impacting its valuation and stakeholder base.

The current Cytek Biosciences ownership is largely dominated by institutional investors, who collectively held 60.91% of the company's shares as of 2025. This significant institutional backing influences the company's strategic direction and financial reporting standards. As of March 31, 2025, major institutional shareholders included BlackRock, Inc., with 18,069,282 shares (approximately 14.20%), and Vanguard Group Inc., holding 9,622,008 shares (approximately 7.56%). Other key institutional investors are Ra Capital Management LP (13,381,054 shares, 10.52%), Brown Capital Management LLC (7,463,967 shares, 5.87%), and Hillhouse Capital Advisors, Ltd. (6,657,030 shares, 5.23%). Insiders, including the founders, collectively owned 10.33% of the company's stock as of the same date. Specifically, co-founder Dr. Wenbin Jiang directly owns 4.14% of the company's shares, and co-founder Dr. Ming Yan directly owns 4.75% as of 2025. Understanding these Cytek ownership details is crucial for grasping the company's financial landscape and its position within the broader market, especially when considering its Competitors Landscape of Cytek.

Key Cytek Biosciences Stakeholders

Institutional investors and company insiders are the primary stakeholders in Cytek Biosciences, shaping its governance and strategic decisions.

• Institutional investors own 60.91% of the company as of 2025.
• BlackRock, Inc. is a major institutional shareholder with approximately 14.20%.
• Vanguard Group Inc. holds approximately 7.56% of outstanding shares.
• Company co-founders Dr. Wenbin Jiang and Dr. Ming Yan hold significant insider stakes.

The Board of Directors at Cytek Biosciences is instrumental in shaping the company's strategic path and ensuring robust governance. As of June 2025, the board includes co-founders Dr. Wenbin Jiang, who also serves as CEO and Chairman, and Dr. Ming Yan, the Chief Technology Officer and a director. They are joined by several independent directors, bringing diverse expertise to the biotech firm.

Cytek Biosciences adheres to a standard one-share-one-vote system for its common stock, a common practice for publicly traded entities with substantial institutional backing. At the annual meeting on June 18, 2025, a significant portion of the outstanding shares, approximately 81.4% of the 127,599,142 shares, were represented. Shareholders possess one vote per share owned as of the record date, April 21, 2025. While no major proxy disputes have been documented, the voting outcomes for director re-elections in June 2025, including votes withheld for Deborah Neff, suggest some shareholder considerations regarding board composition.

Understanding Cytek's Governance

The structure of Cytek Biosciences' board of directors is designed to provide both operational leadership and independent oversight. This composition is key to navigating the complexities of the biotechnology sector.

• Co-founders Dr. Wenbin Jiang and Dr. Ming Yan hold key leadership positions.
• Independent directors bring external expertise to the board.
• A one-share-one-vote policy governs shareholder voting power.
• Shareholder participation was high at the June 2025 annual meeting.
• The company's Revenue Streams & Business Model of Cytek is influenced by its strategic direction.

Cytek Biosciences has seen shifts in its ownership structure over the last three to five years, marked by strategic financial decisions and evolving investor landscapes. These developments are crucial for understanding the company's current and future trajectory in the market.

Institutional investors now hold a significant majority, exceeding 60% of Cytek Biosciences' outstanding shares, reflecting a broader industry trend of increasing institutional ownership. Despite natural founder dilution that can occur with company growth and public offerings, the founders, Drs. Jiang and Yan, continue to maintain substantial insider stakes, underscoring their ongoing commitment to the company. There have been no public announcements regarding potential privatization or new strategic listings in the immediate future. The company remains actively engaged with the investment community, with scheduled participation in investor conferences in September and August 2025. This engagement, coupled with the company's financial performance, with total revenue reaching $200.5 million in 2024 and an anticipated revenue range of $204 million to $212 million for 2025, indicates a focus on sustained growth and shareholder value. For a deeper understanding of the company's journey, one might review its Brief History of Cytek.

Shareholder Composition

Institutional investors represent over 60% of Cytek Biosciences' outstanding shares. Founders maintain significant insider stakes.

Capital Allocation Strategy

The company authorized a $50 million stock repurchase program for 2025. In 2024, approximately $21.6 million was used for share repurchases.

Financial Performance Indicators

Full-year 2024 revenue reached $200.5 million. Projected revenue for 2025 is between $204 million and $212 million.

Investor Engagement

Cytek Biosciences is actively participating in investor conferences in September and August 2025. This signals ongoing communication with the investment community.